Sharon Hesterlee, PhD, on Collaborating to Expand Therapy Development to More Dystrophies
November 25th 2023The chief research officer of the Muscular Dystrophy Association discussed the need for disease-modifying therapies in other muscular dystrophies and programs the association has announced to this end.
Xaviar Michael Jones, MD, on Expanding Horizons in RNA Therapeutics Through Collaboration
November 21st 2023The postdoctoral research fellow at Cedars Sinai Medical Center discussed the future of RNA therapy in the context of research in systemic sclerosis he presented at AHA’s Scientific Sessions 2023.
Brett Kopelan, MA, on the Future Treatment of Epidermolysis Bullosa With Advanced Therapeutics
October 29th 2023In observance of Epidermolysis Bullosa Awareness Week, the executive director of debra of America discussed how a combination of advanced and topical approaches may represent the future of EB treatment.
David Rawlings, MD, on the Potential of Engineered Treg Cells to Treat Autoimmune Diseases
October 24th 2023The director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute discussed preclinical research on overcoming limitations of Treg cells through genetic engineering.